Insider Selling: Guardant Health (NASDAQ:GH) CEO Sells $21,674,463.12 in Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 143,028 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $151.54, for a total transaction of $21,674,463.12. Following the completion of the sale, the chief executive officer owned 1,881,336 shares in the company, valued at approximately $285,097,657.44. This trade represents a 7.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The shares were sold at an average price of $150.79, for a total value of $17,638,207.88.
• On Wednesday, May 20th, Amirali Talasaz sold 210,000 shares of Guardant Health stock. The stock was sold at an average price of $109.89, for a total transaction of $23,076,900.00.
• On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The shares were sold at an average price of $100.32, for a total value of $5,016,000.00.

Guardant Health Trading Down 1.6%

Shares of GH stock opened at $167.98 on Friday. The firm has a fifty day moving average price of $118.33 and a 200 day moving average price of $105.66. The company has a market cap of $22.27 billion, a P/E ratio of -49.55 and a beta of 1.59. Guardant Health, Inc. has a 12 month low of $40.35 and a 12 month high of $172.60.

Institutional Trading of Guardant Health

Several large investors have recently added to or reduced their stakes in GH. V Square Quantitative Management LLC purchased a new position in shares of Guardant Health in the fourth quarter valued at $27,000. Chesapeake Asset Management LLC acquired a new position in shares of Guardant Health in the 4th quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Guardant Health during the fourth quarter valued at $31,000. Elyxium Wealth LLC bought a new stake in shares of Guardant Health during the 4th quarter valued at about $35,000. Finally, Parallel Advisors LLC lifted its holdings in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Mizuho increased their price target on shares of Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Guggenheim increased their price objective on Guardant Health from $135.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday. Royal Bank Of Canada initiated coverage on shares of Guardant Health in a research report on Thursday, June 11th. They set an “outperform” rating and a $185.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $147.32.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.